Prognostic Value of Systemic Immune Inflammation Index in Squamous Cell Lung Cancer
Open Access
- 25 March 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2219
Abstract
Background/Objectives: Squamous cell lung cancer (SCC) presents a significant treatment challenge due to its poor prognosis and limited therapeutic options. In many resource-limited countries, access to advanced molecular testing is often unavailable, making the identification of novel and reliable prognostic markers crucial for improving patient selection for systemic treatments. Methods: This single-center, retrospective study investigated the prognostic value of inflammatory biomarkers, including the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), in 134 patients diagnosed with SCC. Patients were stratified into groups based on optimal cut-off values determined by ROC analysis for each biomarker. Results: Elevated levels of the SII, NLR, and PLR were significantly associated with shorter overall survival in patients with SCC (all p < 0.05). Conclusions: These easily accessible and cost-effective laboratory parameters are particularly valuable in settings where molecular testing is not available, aiding in the identification of high-risk patients and optimizing treatment selection for chemotherapy.Keywords
This publication has 25 references indexed in Scilit:
- Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancerScientific Reports, 2024
- Prognostic value of the combined preoperative plasma fibrinogen and systemic inflammatory indexes in ESCC patientsDiscover Oncology, 2023
- Improving access to immunotherapy in low- and middle-income countriesAnnals of Oncology, 2022
- The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysisClinical Epidemiology and Global Health, 2021
- Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysisAnnals of Medicine, 2021
- Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patientsRespiratory Medicine and Research, 2020
- Early squamous cell lung carcinoma: prognostic biomarkers for the manyThorax, 2019
- Platelet‐to‐lymphocyte ratio predicts the prognosis of patients with non‐small cell lung cancer treated with surgery and postoperative adjuvant chemotherapyThoracic Cancer, 2017
- Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapyCancer Immunology, Immunotherapy, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011